The TF:VIIa Complex: Clinical Significance, Structure-function Relationships and Its Role in Signaling and Metastasis

Summary

In healthy humans, blood vessel-tissue factor is found primarily in the adventitia and thus physically separated from coagulation factors, which mainly circulate in an inactive form. Following injury, TF is exposed to blood and initiates the coagulation cascade. The resulting fibrin formation is an essential part for the initial repair of vessel damage to minimize blood-loss (reviewed by (1-4). Therefore, TF may be considered to form a hemostatic sheath around blood vessels essential for hemostasis and appears to be essential for life inasmuch as no TF deficiency has been reported and TF knockout mice do not survive beyond the perinatal period.

• References

• 1 Nemerson Y. Tissue Factor and Hemostasis. Blood 1988; 71: 1-8.
• 2 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
• 3 Camerer E, Kolsto AB, Prydz H. Cell Biology of Tissue Factor, the principal initiator of blood coagulation. Thrombosis Research 1996; 81: 1-41.
• 4 Rapaport SI, Rao LVM. The Tissue Factor Pathway: How it has become a “Prima Ballerina”. Thromb Haemost 1995; 74: 7-17.
• 5 Giesen PLA, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
• 6 Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Y. Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-32.
• 7 Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest 1996; 75: 451-61.
• 8 Libby P. Changing concepts of atherogenesis. J Internal Medecine 2000; 247: 349-58.
• 9 Zeldis SM, Nemerson Y, Pitlick FA, Lentz TL. Tissue Factor (thromboplastin): localization to plasma membranes by peroxidase-conjugated antibodies. Science 1972; 175: 766-8.
• 10 Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD, Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997; 78: 200-4.
• 11 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl Acad Sci USA 1989; 86: 2839-43.
• 12 Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-32.
• 13 Fuster V, Badimon JJ, Chesebro JH, Fallon JT. Plaque rupture, thrombosis, and therapeutic implications. Haemostasis 1996; 26: 269-84.
• 14 Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
• 15 Niemetz J. Coagulant activity of leukocytes. J Clin Invest 1972; 51: 307-13.
• 16 Prydz H, Allison AC. Tissue thromboplastin activity of isolated human monocytes. Thromb Haemost 1978; 39: 582-91.
• 17 Edwards RL, Rickles FR. The role of leukocytes in the activation of blood coagulation. Seminars in Hematology 1992; 29: 202-12.
• 18 Rickles FR, Hair GA, Zeff RA, Lee E, Bona RD. Tissue factor expression in human leukocytes and tumor cells. Thromb Haemost 1995; 74: 391-5.
• 19 Østerud B.. Cellular interactions in tissue factor expression by blood monocytes. Blood Coagulation and Fibrinolysis 1995; 6: S20-S25.
• 20 Lerner RG, Goldstein R, Nelson JC. Production of thromboplastin (tissue factor) and thrombi by polymorphonuclear neutrophilic leukocytes adhering to vein walls. Thrombosis Research 1977; 11: 11-22.
• 21 Romson GD, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 1983; 67: 1016-23.
• 22 Todoroki H, Nakamura S, Higure A, Okamoto K, Akahane K, Takeda S, Nagata N, Ito H, Ohsato K. Tissue factor expression in monkey and human neutrophils and its function. Thromb Haemost. 1999 Supplement: 463, Abstract.
• 23 Tipping PG, Erlich JH, Apostolopoulos J, Mackman N, Loskutoff D, Holdsworth SR. Glomerular tissue factor expression in crescentic glomerulonephritis. Am J Pathol 1995; 147: 1736-48.
• 24 Higure A, Okamoto K, Hirata K, Todoroki H, Nagafuchi Y, Takeda S, Katoh H, Itoh H, Ohsato K, Nakamura S. Macrophages and neutrophils infiltrating into the liver are responsible for tissue factor expression in a rabbit model of acute obstructive cholangitis. Thromb Haemost 1996; 75: 791-5.
• 25 Todoroki H, Nakamura S, Higure A, Okamoto K, Takeda S, Nagata N, Itoh H, Ohsato K. Neutrophils express tissue factor in a monkey model of sepsis. Surgery 2000; 127: 209-16.
• 26 Kjalke M, Sørensen O, Borregaard N, Ezban M, Kristensen AT. Tissue factor expression by rabbit and human neutrophils. Thromb Haemost. 1999 Supplement: 761 (Abstr no. 2404).
• 27 Timmerman JJ, Keller TT, Reitsma PH, Cate HT. Tissue factor expression by human granulocytes is regulated by lipopolysaccharide (LPS). Thromb Haemost. 1999 Supplement: 701 (Abstr no. 2213).
• 28 Østerud B, Rao LV, Olson JO. Induction of tissue factor expression in whole blood: lack of evidence for the presence of tissue factor expression in granulocytes. Thromb Haemost 2000; 83: 861-7.
• 29 Giesen PLA, Fyfe BS, Fallon JT, Roque M, Mendlowitz M, Rossikhina M, Guha A, Badimon JJ, Nemerson Y, Taubman MB. Intimal tissue factor activity is released from the arterial wall after injury. Thromb Haemost 2000; 83: 622-8.
• 30 Schecter AD, Spirn B, Rossikhina M, Giesen PLA, Bogdanov V, Fallon JT, Fisher EA, L.M. Schnapp LM, Y. Nemerson Y, Taubman MB. Release of active tissue factor by human arterial smooth muscle cells. Circ Res 2000; 87: 126-32.
• 31 Kagawa H, Komiyama Y, Nakamura S, Miyake T, Miyazaki Y, Hamamoto K, Masuda M, Takahashi H, Nomura S, Fukuhara S. Expression of functional tissue factor on small vesicles of lipopolysaccharide-stimulated human vascular endothelial cells. Thrombosis Research 1998; 91: 297-304.
• 32 Mallat Z, Hugel B, Ohan J, Lesèche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human athero-sclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-53.
• 33 Carson SD, Perry GA, Pirruccello SJ. Fibroblast tissue factor: calcium and ionophore induce shape changes, release of membrane vesicles, and redistribution of tissue factor antigen in addition to increased procoagulant activity. Blood 1994; 84: 526-34.
• 34 Dvorak HF, Van DeWater L, Bitzer AM, Dvorak AM, Anderson D, Harvey VS, Bach R, Davis GL, DeWolf W, Carvalho ACA. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Research 1983; 43: 4334-42.
• 35 Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet J-M, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-3.
• 36 Kim HK, Song KS, Park YS, Yun YS, Shim WH. Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology 2000; 93: 31-6.
• 37 Nieuwland R, Berckmans RJ, McGregor S, Romijn FPHTM, Westendorp RGJ, Hack CE, Sturk A. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930-5.
• 38 Combes V, Simon A-C, Grau G-E, Arnoux D, Camoin L, Sabatier F, Murtin M, Sanmarco M, Sampol J, Dignat-George F. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. Journal of Clinical Investigation 1999; 104: 93-102.
• 39 Lee WH, Lee Y, Kim JR, Chu JA, Lee AY, Jung JO, Kim JS, Kim S, Seo JD, Rhee SS, Park JE. Activation of monocytes, t-lymphocytes and plasma inflammatory markers in angina patients. Exp Mol Med 1999; 31: 159-64.
• 40 Soejima H, Ogawa H, Yasue H, Kaikita K, Takazoe K, Nishiyama K, Misumi K, Miyamoto S, Yoshimura S, Kugiyama K, Nakamura S, Tsuji I. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999; 34: 983-8.
• 41 Gando S, Nanzaki S, Sasaki D, Kemmotsu O. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998; 79: 1111-5.
• 42 Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya D, Mori Y, Shiku H. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1997; 55: 169-74.
• 43 Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 1997; 77: 222-3.
• 44 Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-23.
• 45 Lowe GDO, Machado SG, Krol WF, Barton BA, Forbes CD. White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost 1985; 54: 700-3.
• 46 Corre F, Lellouch J, Schwartz D. Smoking and leucocyte-counts. The Lancet 1971; September (Suppl. 18) 632-4.
• 47 Friedman GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction. N Engl J Med 1974; 290: 1275-8.
• 48 Matetzky S, Tani S, Kangavari S, Dimayuga P, Yano J, Xu H, Chyu K-Y, Fishbein MC, Shah PK, Cercek B. Smoking increases tissue factor expression in atherosclerosis plaques. Implications for plaque thrombogenicity. Circulation 2000; 102: 602-4.
• 49 Kirchhofer D, Riederer MA, Baumgartner H-R.. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 1997; 89: 1270-8.
• 50 Hagberg IA, Roald HE, Lyberg T. Adhesion of leukocytes to growing arterial thrombi. Thromb Haemost 1998; 80: 852-8.
• 51 R.M. Barstad RM, M.J. Hamers MJ, P. Kierulf P, A. B. Westvik AB, Sakariassen KS. Procoagulant human monocytes mediate tissue factor/ factor VIIa-dependent platelet-thrombus formation when exposed to flowing nonanticoagulated human blood. Arterioscler Thromb Vasc Biol 1995; 15: 11-6.
• 52 Sakariassen KS, Joss R, Muggli R, Kuhn H, Tschopp TB, Sage H, Baumgartner H-R.. Collagen type III induced ex vivo thrombogenesis in humans. Role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis 1990; 10: 276-84.
• 53 Hernandez MR, Escolar G, Bozzo J, Galan AM, Ordinas A. Inhibition of fibrin deposition on the subendothelium by a monoclonal antibody to polymorphonuclear leukocyte integrin CD11b: studies in a flow system. Haematologica 1997; 82: 566-71.
• 54 Downing LJ, Wakefield TW, Strieter RM, Prince MR, Londy FJ, Fowlkes JB, Hulin MS, Kadell AM, Wilke CA, Vrown SL, Wrobleski SK, Burdick MD, Anderson DC, Greenfield LJ. Anti-P-Selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg 1997; 25: 816-28.
• 55 Eppihimer MJ, Schaub RG. P-Selectin-Dependent Inhibition of Thrombosis During Venous Stasis. Arterioscler Thromb Vasc Biol 2000; 20: 2483-8.
• 56 Wakefiled TW, Strieter R, Schaub R, Myers DD, Prince MR, Wrobleski SK, Londy FJ, Kadell AM, Brown SL, Hanke PK, Greenfield LJ. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J Vasc Surgery 2000; 31: 309-24.
• 57 Leatham EW, Bath P, Tooze JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J 1995; 73: 10-3.
• 58 Misumi K, Ogawa H, Yasue H, Soejima H, Suefuji H, Nishiyama K, Takazoe K, Kugiyama K, Tsuji I, Kumeda K, Nakamura S. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998; 81: 22-6.
• 59 Moreno PR, Bernardi VH, López-Cuéllar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94: 3090-7.
• 60 Belch JJF. The role of the white blood cell in arterial disease. Blood Coagulation and Fibrinolysis 1990; 1: 183-92.
• 61 Suefuji H, Ogawa H, Yasue H, Kaikita K, Soejima H, Motoyama T, Mizuno Y, Oshima S, Saito T, Tsuji I, Kumeda K, Kamikudo Y, Nakamura S. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134: 253-9.
• 62 Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-13.
• 63 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstitued phospholidid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25: 4007-20.
• 64 A.S. Wolberg AS, D.M. Monroe DM, H. R. Roberts HR, Hoffman MR. Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine -dependent and -independent mechanisms. Blood Coagulation and Fibrinolysis 1999; 10: 201-10.
• 65 Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA 1990; 87: 6995-9.
• 66 R. Consonni R, Bertina RM. Antigenic and functional expression of tissue factor in endotoxin stimulated U937 cells: regulation of activity by calcium ionophore A23187. Thromb Haemost 1995; 74: 904-9.
• 67 Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Laboratory Investigation 1996; 75: 281-9.
• 68 Wakita K, Stearns-Kurosawa DJ, Marumoto Y. The effect of calcium ionophore A23187 on tissue factor activity and mRNA in endothelial cells. Thromb Res 1994; 74: 95-103.
• 69 Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, Kohtz DS, Fallon JT, Nemerson Y, Taubman MB. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997; 100: 2276-85.
• 70 Agnelli ALG, Büller H, Ginsberg J, Heit JR, Vlasuk G, Gent M. A dose-response study of the factor VIIa/Tissue factor inhibitor rNAPc2 in the prevention of postoperative venous thrombosis in patients undergoing total knee arthroplasty. Blood 2000; 96: 491 abstract.
• 71 F. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87: 6934-8.
• 72 Banner DW, D’Arcy A, Chène C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-6.
• 73 Ruf W, Kelly CR, Schullek JR, Martin DMA, Polikarpov I, Boys CWG, Tuddenham EGD. S.. Edgington TS Energetic contributions and topo-graphical organization of ligand binding residues of tissue factor. Biochemistry 1995; 34: 6310-5.
• 74 Ashton AW, Kemball-Cook G, Johnson DJD, Martin DMA, O’Brien DP, Tuddenham EGD, Perkins SJ. Factor VIIa and the extracellular domains of human tissue factor form a compact complex: a study by X-ray and neutron solution scattering. FEBS lett. 1995; 374: 141-6.
• 75 Kelley RF, Costas KE, O’Connell MP, Lazarus RA. Analysis of the factor VIIa binding site on human tissue factor: effects of tissue factor mutations on the kinetics and thermodynamics of binding. Biochemistry 1995; 34: 10383-92.
• 76 Gibbs CS, McCurdy SN, Leung LLK, Paborsky LR. Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis. Biochemistry 1994; 33: 14003-10.
• 77 Ruf W, Miles DJ, Rehemtulla A, Edgington TS. Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII. J Biol Chem 1992; 267: 22206-10.
• 78 Ruf W, Schullek JR, Stone MJ, Edgington TS. Mutational mapping of functional residues in tissue factor: Identification of factor VII recognition determinants in both structural modules of the predicted cytokine receptor homology domain. Biochemistry 1994; 33: 1565-72.
• 79 Rehemtulla A, Ruf W, Edgington TS. The integrity of the cysteine 186 – cysteine 209 bond of the second disulfide loop of tissue factor is required for binding of factor VII. J Biol Chem 1991; 266: 10294-9.
• 80 Cooper DN, Millar DS, Wacey A, Banner DW, Tuddenham EGD. Inherited factor VII deficiency: molecular genetics and pathophysiology. Thromb Haemost 1997; 78: 151-60.
• 81 O’Brien DP, Kemball-Cook G, Hutchinson AM, Martin DMA, Johnson DJD, Byfield PGH, Takamiya O, Tuddenham EGD, McVey JH. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). Biochemistry 1994; 33: 14162-9.
• 82 Chaing S, Clarke B, Sridhara S, Chu K, Friedman P, VanDusen W, Roberts HR, Blajchman M, Monroe DM, High KA. Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. Blood 1994; 83: 3524-35.
• 83 Ruf W. The interaction of activated factor VII with tissue factor: insight into the mechanism of cofactor-mediated activation of activated factor VII. Blood Coag Fibrinol 1998; 9 (Suppl. 01) S73-S78.
• 84 Kelly CR, Schullek JR, Ruf W, Edgington TS. Tissue factor residue Asp44 regulates catalytic function of the bound proteinase factor VIIa. Biochem J 1996; 315: 145-51.
• 85 Dickinson CD, Kelly CR, Ruf W. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. Proc Natl Acad Sci USA 1996; 93: 14379-84.
• 85a Zur M, Radcliffe RD, Oberdick J, Nemerson Y. The dual role of factor VII in blood coagulation. Initiation and inhibition of a proteolytic system by a zymogen. J Biol Chem 1982; 257: 5623-31.
• 86 Dickinson CD, Ruf W. Active site modification of factor VIIa affects interactions of the protease domain with tissue factor. J Biol Chem 1997; 272: 19875-9.
• 86a Broze Jr GJ. Binding of human factor VII and VIIa to monocytes. J Clin Invest 1982; 70: 526-35.
• 87 Muller YA, Ultsch MH, Kelley RF, de Vos AM. Structure of the extra-cellular domain of human tissue factor: location of the factor VIIa binding site. Biochemistry 1994; 33: 10864-70.
• 88 Harlos K, Martin DMA, O’Brien DP, Jones EY, Stuart DI, Polikarpov I, Miller A, Tuddenham EGD, Boys CWG. Crystal structure of the extra-cellular region of human tissue factor. Nature 1994; 370: 662-6.
• 89 Zhang E, St. Charles R Tulinsky A. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. J Mol Biol 1999; 285: 2089-104.
• 90 Waxman E, Laws WR, Laue TM, Nemerson Y, Ross JBA. Human factor VIIa and its complex with soluble tissue factor: evaluation of asymmetry and conformational dynamics by ultracentrifugation and fluorescence anisotropy decay methods. Biochemistry 1993; 32: 3005-12.
• 91 McCallum CD, Hapak RC, Neuenschwander PF, Morrissey JH, Johnson AE. The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor. J Biol Chem 1996; 271: 28168-75.
• 92 McCallum CD, Su B, Neuenschwander PF, Morrissey JH, Johnson AE. Tissue factor positions and maintains the factor VIIa active site far above the membrane surface even in the absence of the factor VIIa Gla domain. J Biol Chem 1997; 272: 30160-6.
• 93 Lu R, Esmon NL, Esmon CT, Johnson AE. The active site of thrombinthrombomodulin complex. A fluorescence energy transfer measurement of its distance above the membrane surface. J Biol Chem 1989; 264: 12956-62.
• 94 Mutucumarana VP, Duffy EJ, Lollar P, Johnson AE. The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study. J Biol Chem 1992; 267: 17012-21.
• 95 Husten EJ, Esmon CT, Johnson AE. The active site of blood coagulation factor Xa. Its distance from the phospholipid surface and its conformational sensitivity to components of the prothrombinase complex. J Biol Chem 1987; 262: 12953-61.
• 96 Freedman SJ, Furie BC, Furie B, Baleja JD. Structure of the calcium ion-bound g-carboxyglutamic acid-rich domain of factor IX. Biochemistry 1995; 34: 12126-37.
• 97 Freedman SJ, Blostein MD, Baleja JD, Jacobs M, Furie BC, B. Furie B. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. J Biol Chem 1996; 271: 16227-36.
• 98 Sunnerhagen M, Forsén S, Hoffrén A-M, Drakenberg T, Teleman O, Stenflo J. Structure of the Ca²⁺-free GLA domain sheds light on membrane binding of blood coagulation proteins. Nature Struct Biol 1995; 2: 504-9.
• 99 Christiansen WT, Jalbert LR, Robertson RM, Jhingan A, Prorok M, Castellino FJ. Hydrophobic amino acid residues of human anticoagulation protein C that contribute to its functional binding to phospholipid vesicles. Biochemistry 1995; 34: 10376-82.
• 100 Zhang L, Castellino FJ. The binding energy of human coagulation protein C to acidic phospholipid vesicles contains a major contribution from leucine 5 in the γ-carboxyglutamic acid domain. J Biol Chem 1994; 269: 3590-5.
• 101 Ruf W, Miles DJ, Rehemtulla A, Edgington TS. Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex. J Biol Chem 1992; 267: 6375-81.
• 102 Roy S, Hass PE, Bourell JH, Henzel WJ, Vehar GA. Lysine residues 165 and 166 are essential for the cofactor function of tissue factor. J Biol Chem 1991; 266: 22063-6.
• 103 Huang Q, Neuenschwander PF, Rezaie AR, Morrissey JH. Substrate recognition by tissue factor-factor VIIa. Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X. J Biol Chem 1996; 271: 21752-7.
• 104 Kirchhofer D, Lipari MT, Moran P, Eigenbrot C, Kelley RF. The tissue factor region that interacts with substrates factor IX and factor X. Biochemistry 2000; 39: 7380-7.
• 105 Ruf W, Shobe J, Rao SM, Dickinson CD, Olson A, Edgington TS. Importance of factor VIIa Gla-domain residue Arg-36 for recognition of the macromolecular substrate factor X Gla-domain. Biochemistry 1999; 38: 1957-66.
• 106 Martin DMA, O’Brien DP, Tuddenham EGD, Byfield PGH. Synthesis and characterization of wild-type and variant γ-carboxylutamic acid-containing domains of factor VII. Biochemistry 1993; 32: 13949-55.
• 107 Wu P-C, Hamaguchi N, Yu Y-S, Shen M-C, Lin S-W.. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by factor VIIa-tissue factor complex. Thromb Haemost 2000; 84: 626-34.
• 108 Zhong D, Smith KJ, Birktoft JJ, Bajaj SP. First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa. Proc Natl Acad Sci USA 1994; 91: 3574-8.
• 109 Fiore MM, Neuenschwander PF, Morrissey JH. An unusual antibody that blocks tissue factor/factor VIIa function by inhibiting cleavage only of macromolecular substrates. Blood 1992; 80: 3127-34.
• 110 Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TFoVIIa complex is a potent anticoagulant in plasma. Thromb Haemost 1991; 66: 529-33.
• 111 Huang M, Syed R, Stura EA, Stone MJ, Stefanko RS, Ruf W, Edgington TS, Wilson IA. The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TFo5G9 complex. J Mol Biol 1998; 275: 873-94.
• 112 Kirchhofer D, Moran P, Chiang N, Kim J, Riederer MA, Eigenbrot C, Kelley RF. Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies. Thromb Haemost 2000; 84: 1072-81.
• 113 Ruf W. Factor VIIa residue Arg290 is required for efficient activation of the macromolecular substrate factor X. Biochemistry 1994; 33: 11631-6.
• 114 Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, Tulinsky A, Westbrook M, Maraganore JM. Structure of hirugen and hirulog 1 complexes of α-thrombin. J Mol Biol 1991; 221: 1379-93.
• 115 Stubbs MT, Bode W. A player of many parts: The spotlight falls on thrombin’s structure. Thromb Res 1993; 69: 1-58.
• 116 Naski MC, Fenton JW II, Maraganore JM, Olson ST, Shafer JA. The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of α-thrombin on fibrinogen. J Biol Chem 1990; 265: 13484-9.
• 117 Dennis MS, Eigenbrot C, Skelton NJ, Ultsch MH, Santell L, Dwyer MA, O’Connell MP, Lazarus RA. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 2000; 404: 465-70.
• 118 Neuenschwander PF, Branam DE, Morrissey JH. Importance of substrate composition, pH and other variables on tissue factor enhancement of factor VIIa activity. Thromb Haemost 1993; 70: 970-7.
• 119 Butenas S, Ribarik N, Mann KG. Synthetic substrates for human factor VIIa and factor VIIa-tissue factor. Biochemistry 1993; 32: 6531-8.
• 120 Higashi S, Nishimura H, Fujii S, Takada K, Iwanaga S. Tissue factor potentiates the factor VIIa-catalyzed hydrolysis of an ester substrate. J Biol Chem 1992; 267: 17990-6.
• 122 Kemball-Cook H, Johnson DJD, Tuddenham EGD, Harlos K. Crystal structure of active site-inhibited human coagulation factor VIIa (des-Gla). J Struct Biol 1999; 127: 213-23.
• 123 Pike ACW, Brzozowski AM, Roberts SM, Olsen OH, Persson E. Structure of human factor VIIa and its implications for the triggering of blood coagulation. Proc Natl Acad Sci USA 1999; 96: 8925-30.
• 124 Higashi S, Matsumoto N, Iwanaga S. Molecular Mechanism of tissue factor-mediated acceleration of factor VIIa activity. J Biol Chem 1996; 271: 26569-74.
• 125 Dickinson CD, Shobe J, Ruf W. Influence of cofactor binding and active site occupancy on the conformation of the macromolecular substrate exosite of factor VIIa. J Mol Biol 1998; 277: 959-71.
• 126 Huber R, W. Bode W. Structural basis of the activation and action of trypsin. Acc Chem Res 1978; 11: 114-22.
• 127 Vijayalakshmi J, Padmanabhan KP, Mann KG, Tulinksy A. The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Protein Sci 1994; 3: 2254-71.
• 128 Wang D, Bode W, Huber R. Bovine chymotrypsinogen A: x-ray crystal structure analysis and refinement of a new crystal form at 1.8 Å resolution. J Mol Biol 1985; 185: 595-624.
• 129 Higashi S, Iwanaga S. Molecular interaction between factor VII and tissue factor. Int J Hematol 1998; 67: 229-41.
• 130 D. Kirchhofer D, Banner DW. Molecular and structural advances in tissue factor-dependent coagulation. Trends Cardiovasc Med 1997; 7: 316-24.
• 131 Ruf W, Dickinson CD. Allosteric regulation of the cofactor-dependent serine protease coagulation factor VIIa. Trends Cardiovasc Med 1998; 8: 350-6.
• 132 Eigenbrot C, Kirchhofer D, Dennis MS, Santell L, Lazarus RA, Stamos J. H.. Ultsch MH The factor VII zymogen structure reveals re-registration of β-strands during activation. Structure 2001; 9: 627-36.
• 133 Petrovan RJ, Ruf W. Residue Met¹⁵⁶ contributes to the labile enzyme conformation of coagulation factor VIIa. J Biol Chem 2000; 39: 14457-63.
• 134 Roussel P, Bradley M, Kane P, Bailey C, Arnold R, Cross A. Inhibition of the tissue factor/factor VIIa complex – lead optimization using combinatorial chemistry. Tetrahedron 1999; 55: 6219-30.
• 135 Kohrt JT, Filipski KJ, Rapundalo ST, Cody WL, Edmunds JJ. An efficient synthesis of 2-[3-(4-amidinophenylcarbamoyl)naphtalen-2-yl]-5[(2,2-methylpropyl)carbamoyl]benzoic acid: a factor VIIa inhibitor discovered by the Ono Pharmaceutical Company. Tetrahedron Lett 2000; 41: 6041-4.
• 136 Nemerson Y, Gentry R. An ordered addition, essential activation model of the tissue factor pathway of coagulation: Evidence for a conformational cage. Biochemistry 1986; 25: 4020-33.
• 137 Baugh RJ, Dickinson CD, Ruf W, Krishnaswamy S. Exosite interactions determine the affinity of factor X for the extrinsic Xase complex. J Biol Chem 2000; 275: 28826-33.
• 138 Shobe J, Dickinson CD, Edgington TS, Ruf W. Macromolecular substrate affinity for the tissue factor-factor VIIa complex is independent of scissile bond docking. J BiolChem 1999; 274: 24171-5.
• 139 Krishnaswamy S, Betz A. Exosites determine macromolecular substrate recognition by prothrombinase. Biochemistry 1997; 36: 12080-6.
• 140 Broze Jr GJ, Majerus PW. Purification and properties of human coagulation factor VII. J Biol Chem 1980; 255: 1242-7.
• 141 Radcliffe R, Nemerson Y. Activation and control of factor VII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor VII. J Biol Chem 1975; 250: 388-95.
• 142 Seligsohn U, Østerud B, Brown SF, Griffin JH, Rapaport SI. Activation of human factor VII in plasma and in purified systems. Roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest 1979; 64: 1056-65.
• 143 Neuenschwander PF, Fiore MM, Morrissey JH. Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem 1993; 268: 21489-92.
• 144 Nakagaki T, Foster DC, Berkner KL, Kisiel W.. Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry 1991; 30: 10819-24.
• 145 Pedersen AH, Lund-Hansen T, Bisgaard-Frantzen H, Olsen F, Petersen LC. Autoactivation of human recombinant coagulation factor VII. Biochemistry 1989; 28: 9331-6.
• 146 Kazama Y, Hamamoto T, Foster DC, Kisiel W. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J Biol Chem 1995; 270: 66-72.
• 147 Römisch J, Feussner A, Vermöhlen S, Stöhr H-A. A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coag Fibrinol 1999; 10: 471-9.
• 148 Rao LVM, Rapaport SI, Bajaj SP. Activation of human factor VII in the initiation of tissue factor-dependent coagulation. Blood 1986; 68: 685-91.
• 149 Rao LVM, Rapaport SI. Activation of factor VII bound to tissue factor: A key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-91.
• 150 Butenas S, Mann KG. Kinetics of human factor VII activation. Biochemistry 1996; 35: 1904-10.
• 151 Lawson JH, Butenas S, Mann KG. The evaluation of complex-dependent alterations in human factor VIIa. J Biol Chem 1992; 267: 4834-43.
• 152 Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thromb Res 1985; 40: 351-8.
• 153 Dittmar S, Ruf W, Edgington TS. Influence of mutations in tissue factor on the fine specificity of macromolecular substrate activation. Biochem J 1997; 321: 787-93.
• 154 Kirchhofer D, Eigenbrot C, Lipari TM, Moran P, Peek M, Kelley RF. The tissue factor region that interacts with factor Xa in the activation of factor VII. Biochemistry 2001; 40: 675-82.
• 155 Rao LVM, Ruf W. Tissue factor residues Lys¹⁶⁵ and Lys¹⁶⁶ are essential for rapid formation of the quaternary complex of tissue factoroVIIa with Xaotissue factor pathway inhibitor. Biochemistry 1995; 34: 10867-71.
• 156 Østerud B.. Tissue factor: a complex biological role. Thromb Haemost 1997; 78: 755-8.
• 157 Prydz H. A new paradigm for blood coagulation research. Thromb Haemost 2000; 83: 520-2.
• 158 Ruf W, Mueller BM. Tissue factor signaling. Thromb Haemost 1999; 82: 175-82.
• 159 Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 1991; 254: 821-5.
• 160 Patthy L. Evolutionary assembly of blood coagulation proteins. Semin Thromb Hemost 1990; 16: 245-59.
• 161 Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-8.
• 162 Nemerson Y, Gentry R. An ordered addition, essential activation model of the tissue factor pathway of coagulation: evidence for a conformational cage. Biochemistry 1986; 25: 4020-33.
• 163 Dickinson CD, Ruf W. Active site modification of factor VIIa affects interactions of the protease domain with tissue factor. J Biol Chem 1997; 272: 19875-9.
• 164 Sørensen BB, Rao LV. Interaction of activated factor VII and active site-inhibited activated factor VII with tissue factor. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 01) S67-71.
• 165 Leonard BJ, Clarke BJ, Sridhara S, Kelley R, Ofosu FA, Blajchman MA. Activation and active site occupation alter conformation in the region of the first epidermal growth factor-like domain of human factor VII. J Biol Chem 2000; 275: 34894-900.
• 166 Bharadwaj D, Iino M, Kontoyianni M, Smith KJ, Foster DC, Kisiel W. Factor VII central. A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity. J Biol Chem 1996; 271: 30685-91.
• 167 Waxman E, Ross JB, Laue TM, Guha A, Thiruvikraman SV, Lin TC, Konigsberg WH, Nemerson Y. Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. Biochemistry 1992; 31: 3998-4003.
• 168 Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999; 96: 8663-8.
• 169 Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000; 97: 5255-60.
• 170 Saxton MJ. Single-particle tracking: the distribution of diffusion coefficients. Biophys J 1997; 72: 1744-53.
• 171 Schutz GJ, H. Schindler H, Schmidt T. Single-molecule microscopy on model membranes reveals anomalous diffusion. Biophys J 1997; 73: 1073-80.
• 172 Sørensen BB, Freskgård PO, Nielsen LS, Rao LV, Ezban M, Petersen LC. Factor VIIa-induced p44/42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain. J Biol Chem 1999; 274: 21349-54.
• 173 Poulsen LK, Jacobsen N, Sørensen BB, Bergenhem NC, Kelly JD, Foster DDC, Thastrup O, Ezban M, Petersen LC. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem 1998; 273: 6228-32.
• 174 Petersen LC, Thastrup O, Hagel G, Sørensen BB, Freskgård PO, Rao LV, Ezban M. Exclusion of known protease-activated receptors in factor VIIa-induced signal transduction. Thromb Haemost 2000; 83: 571-6.
• 175 Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999; 94: 3413-20.
• 175a Sørensen BB, Persson E, Freskgård P-O, Kjalke M, Ezban M, Williams T, Rao LVM. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997; 272: 11863-8.
• 176 Camerer E, Røttingen JA, Iversen JG, H. Prydz H. Coagulation factors VII and X induce Ca²⁺ oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem 1996; 271: 29034-42.
• 177 Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease [see comments]. Nat Med 1996; 2: 209-15.
• 178 Shoji M, Nawroth PP, Rickles FR. Molecular Mechanisms Linking Thrombosis and Angiogenesis in Cancer. TCM 1997; 7: 52-9.
• 179 Carmeliet P, Mackman N, Moons L, Luther L, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Muller M, Risau W, Edgington TS, Collen D. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73-5.
• 180 Parry GC, Mackman N. Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain. J Clin Invest 2000; 105: 1547-54.
• 180a Rosen ED, Chan JCY, Idusogie E, Clotman F, Vlasuk G, Luther T, Jalbert LR, Albrecht S, Zhong L, Lissens A, Schoonjans L, Moons L, Collen D, Castellino FJ, Carmeliet P. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997; 390: 290-4.
• 181 Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH. Role of tissue factor in metastasis: functions of the cytoplasmic and extra-cellular domains of the molecule. Thromb Haemost 1999; 82: 88-92.
• 182 Ollivier V, Chabbat J, Herbert JM, Hakim J, de Prost D. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol 2000; 20: 1374-81.
• 183 Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998; 91: 2698-703.
• 184 Pendurthi UR, Alok D, Rao LV. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: up-regulation of poly (A) polymerase. Proc Natl Acad Sci USA 1997; 94: 12598-603.
• 185 Pendurthi UR, Allen KE, Ezban M, Rao LV. Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extra-cellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa x tissue factor-induced signal transduction. J Biol Chem 2000; 275: 14632-41.
• 186 Oemar BS, Werner A, Garnier JM, Do DD, Godoy N, Nauck M, Marz W, Rupp J, Pech M, Luscher TF. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 1997; 95: 831-9.
• 187 Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 2000; 275: 6580-5.
• 188 Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983; 2: 41-73.
• 189 Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978; 38: 2651-60.
• 190 Rickles FR. L.. Edwards RL Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31.
• 191 Hu T, Bach RR, Horton R, Konigsberg WH, Todd MB. Procoagulant activity in cancer cells is dependent on tissue factor expression. Oncol Res 1994; 6: 321-7.
• 192 Murray JC. Coagulation and cancer. Br J Cancer 1991; 64: 422-4.
• 193 Constantini S, Kornowski R, Pomeranz S, Rappaport ZH. Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumors. Acta Neurochir 1991; 109: 93-7.
• 194 Mueller BM, Reisfeld A, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89: 11832-6.
• 195 Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-45.
• 196 Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis [see comments]. N Engl J Med 1995; 333: 1757-63.
• 197 Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP. Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320-7.
• 198 Fischer EG, Ruf W, Mueller BM. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 1995; 55: 1629-32.
• 199 Taniguchi T, Kakkar AK, Tuddenham EG, Williamson RC, Lemoine NR. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 1998; 58: 4461-7.
• 200 Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 8205-9.
• 201 Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998; 101: 1372-8.
• 202 Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998; 140: 1241-53.
• 203 Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996; 15: 165-76.
• 204 Camera M, Giesen PL, Fallon J, Aufiero BM, Taubman M, Tremoli E, Nemerson Y.. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 531-7.
• 205 Hopfner K-P, Lang A, Karcher A, Sichler K, Kopetzki E, Brandstetter H, Huber R, Bode W, Engh RA. Coagulation factor IXa: The relaxed conformation of Tyr99 blocks substrate binding. Structure 1999; 7: 989-96.
• 206 Brandstetter H, Kühne A, Bode W, Huber R, von der Saal W, Wirthensohn K, Engh RA. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J Biol Chem 1996; 271: 29988-92.